The ninth batch of drugs in ① involves 42 varieties, including esomeprazole, citicoline, Piracetam, propofol, flurovir group, and capofenjing, such as large varieties; the overall collection of ② continues the previous plan, but there are also some important changes in details, including the extension of the label period to four years; ③ in the protection of the interests of selected enterprises, there is also a continuous policy good in the release.
Science and Technology Innovation Board Daily, Oct. 14 (Reporter Xu Hong)The ninth batch of national drug collection officially kicked off!
On the evening of the 13th, the State-organized Drug Joint Purchasing Office issued a notice on the release of the National centralized Drug Purchasing document (GY-YD2023-2), announcing the formal launch of the ninth batch of state-organized centralized drug procurement.
According to the catalogue of purchased varieties published on the same day42 varieties will be involved in this collection, including esomeprazole, citicoline, Piracetam, propofol, fluroverine and captophenjing..
Judging from the published documents,This collection continues the previous plan as a whole, but there are also some important changes in details. In this regard, some people in the industry who have been involved in many mining activities have concluded that "this collection has been further optimized in terms of rules than before.".
For example, in the procurement cycle, the earliest collection is "12 months from the date of implementation of the results as a procurement cycle", and then according to the number of winning enterprises is subdivided into "the actual number of selected enterprises is 1 or 2, the procurement cycle is 1 year in principle; if the actual number of successful enterprises is 3, the procurement cycle is 2 years in principle; if the actual number of successful enterprises in the country is 4 or more, the procurement cycle is 3 years in principle."
In the eighth batch of collection completed in March this year, the procurement cycle is unified for two years (from the date of the successful selection to December 31, 2025).In the ninth batch, the bid period was further extended to four years.(from the date of implementation of the winning result to December 31, 2027).
In the eyes of the industryIn principle, the extension of the bidding period is more beneficial to the winning bidders, but for some varieties, especially those with higher market share, it may increase the pressure of bidding..
Jin Chunlin, director of Shanghai Health and Health Development Research Center, interprets this.Extending the bidding period to four years can increase the enthusiasm of enterprises to participate in bidding and increase the attractiveness of winning bids..
"according to the existing collection rules, at most ten enterprises of a variety can win the bid, so the market share of each enterprise will be very limited, so extending the bidding period is beneficial to enhance the enthusiasm of enterprises to participate in bidding.Moreover, the extension of the bidding period is also more conducive to the stability of market supply." Jin Chunlin told Science and Technology Innovation Board Daily.
At the same time, Jin Chunlin also pointed outThere is another bright spot worth paying attention to in this collection, that is, through the complement and optimization of a number of rules, in order to prevent enterprises from "encircling the bid"..
Including in the proposed selection rules, collection from the seventh batch, the introduction of "TOP 6" phase-out new rules. This new regulation proposes that the products (enterprises) with the highest order to win the bid shall calculate the ratio according to the highest "unit comparable price" of the same variety / the lowest "unit comparable price" of the same variety, and the top 6 in the descending order of the ratio of all varieties will lose the qualification to be selected again.
In this collection, this rule is updated again, which is adjusted to "the top four in the descending order of the ratio of all varieties cannot be qualified for the proposed selection." At the same time, an item is added, that is, those who rank the last two in the descending order of the ratio of all varieties in this collection will also lose their eligibility for selection in principle, except for the reduction of ≥ 30% or the unit comparable price ≤ 1 yuan per unit declared price compared to the highest effective quoted price.
Other related adjustments include, in order to prevent multiple related enterprises from joining hands to encircle the bid, supporting only one to declare, and proposing for the first time that enterprises can form a consortium to declare, and so on.
The national pilot policy on centralized drug procurement was first implemented in "4-7" cities in December 2018, and so far eight batches and nine rounds of drug procurement have been completed. With the collection policy becoming more and more normalized and mature, the impact on the market is also gradually weakening.
Figure | Price reduction of drugs collected in previous countries
In particular, the reporter noticed that in addition to constantly "checking leaks and filling gaps" in the rules, the reporter noted that in addition to "checking leaks and filling gaps" in the rules, the reporter noticed that the collection collection was in addition to "checking leaks and filling gaps" in the rules.At the level of protecting the interests of the selected enterprises, there are also continuous policy benefits in the release.. For example, shortly after the implementation of the collection policy, the winning varieties will enjoy a preferential medical insurance policy, which can be directly included in the national health insurance catalogue without price reduction.
Recently, National Healthcare Security Administration issued the guidance on strengthening the Management of Medical Insurance payment qualifications of relevant personnel in designated Pharmaceutical institutions (draft for soliciting opinions). The purpose of this document is to strengthen the management of doctors' diagnosis and treatment behavior.Among them, the relevant requirements for doctors to use collection drugs are also put forward, which is expected to further ensure the landing use of the products that have won the bid..
According to the above-mentioned "draft for soliciting opinions", the health insurance department will score and manage doctors' violations, and doctors will not be able to provide health insurance-related services for the time being if the scores are "deducted". The illegal behaviors of doctors mainly include fraudulent insurance fraud, excessive diagnosis and treatment, collection of external medicine, and so on.
According to the document, doctors who violate the rules and use a large number of high-priced non-selected varieties or alternative varieties can be scored 1-3 points (deducted 1-3 points); among drugs with the same common name, drugs of the same quality level and suitable prices have been put up for sale on the centralized procurement platform, and those who still initiate applications for the procurement demand of high-priced drugs of other brands of the same variety shall also be scored 1-3 points (deducted 1-3 points).